November 17 FDA Meeting Could Define the Next Phase for NEO212

DALLAS, Sept. 29, 2026 (GLOBE NEWSWIRE) — (www.InvestorsTape.com) — NeOnc Technologies Holdings (NASDAQ: NTHI) is heading toward another potentially important regulatory milestone, with the U.S. Food and Drug Administration scheduled to meet with the company on November 17, 2026, for an in-person End-of-Phase 1 Type B meeting concerning NEO212, its oral perillyl alcohol-temozolomide conjugate being developed for aggressive central nervous system cancers.

NeOnc plans to seek agency feedback on the proposed patient population, Phase 2 trial design, endpoints, dose selection and the evidence that could ultimately support a future marketing application. The company also intends to discuss potential registrational strategies and whether a future study could potentially support an accelerated-approval pathway.

NEO212 enters that discussion with a completed Phase 1 dose-escalation program and a defined recommended Phase 2 dose of 610 mg, following dose escalation to a protocol-defined maximum tolerated dose of 810 mg. The company has reported early signals of potential activity in heavily pretreated patients, including a patient with recurrent IDH1 wild-type, MGMT-methylated glioblastoma who experienced approximately a 60% tumor reduction and 21 months of disease control. Another heavily pretreated patient with lung cancer metastatic to the brain experienced stable disease for approximately 16 months. These observations remain individual-patient findings rather than controlled evidence of efficacy, making the design and outcome of larger studies critical. NeOnc has also secured UAE IND authorization for NEO212, creating an international clinical-development pathway alongside its U.S. regulatory discussions.

NeOnc CEO Amir Heshmatpour summarized the immediate objective: “This meeting will help us understand FDA’s feedback on the population, study design and endpoints for the next stage of development.” The November meeting follows FDA written feedback earlier this year concerning NEO212’s chemistry, manufacturing and controls program and the planned transition from a capsule to a tablet formulation. That makes the upcoming discussion potentially important not only for clinical strategy, but also for clarifying the practical development path toward a larger study.

The NEO212 story is unfolding alongside meaningful progress from NeOnc’s lead program, NEO100. In August, the company reported topline Phase 2a results in recurrent or progressive Grade III and Grade IV IDH1-mutant glioma, with six-month progression-free survival of 48.9% versus a prespecified 20% benchmark (p=0.0047) and median overall survival of 26.09 months. NeOnc also reported that 86.7% of patients were alive at six months, five of 24 patients remained on treatment at the data cutoff, and one partial response remained ongoing beyond 114 days. The company said it plans to request an FDA Type B meeting to discuss a potential registrational pathway in this setting.

The company has also been building its financial position around those clinical catalysts. In September, NeOnc completed a $15 million registered direct offering priced at $4.20 per share, alongside warrants with a $4.20 exercise price. The financing involved new and existing healthcare-focused institutional investors, with proceeds designated for working capital, general corporate purposes and the redemption of Series A convertible preferred stock. Days later, NeOnc announced that it had redeemed all 6,000 outstanding Series A preferred shares for $6 million in cash, stating that the transaction eliminated the related potential dilution without issuing common shares in the redemption.

There has also been notable insider activity. NeOnc reported in September that its executives had made approximately $629,000 in open-market purchases following the positive NEO100 Phase 2a results, including CEO Amir Heshmatpour’s purchase of an additional 35,000 shares for approximately $115,400 and 111,000 shares purchased by Heshmatpour since the August clinical readout. These purchases are factual disclosures of insider transactions and do not establish future clinical or market performance.

Wall Street has added another layer to the story. Roth Capital analyst Jonathan Aschoff initiated coverage of NeOnc in September with a reported $20 price target, while the research firm identified potential pivotal-trial starts for NEO100 and NEO212 as future development milestones. That is an analyst view rather than a company forecast or regulatory determination.

For NTHI, the November 17 FDA meeting now sits at the center of a broader sequence of catalysts: regulatory feedback for NEO212, continued advancement of NEO100 following its Phase 2a readout, potential registrational discussions, international development in the UAE and further financing and clinical execution.

For investors tracking the CNS biotech space, that makes November 17 a date with potentially significant implications for the company’s development roadmap heading into 2027.

About InvestorsTape.com

At InvestorsTape.com, our mission is simple: deliver financial news that cuts through the noise and shines a spotlight on the companies, innovations, and market forces shaping the next decade of growth. In a landscape dominated by high-frequency headlines and fleeting narratives, we bring clarity, depth, and balance to the stories that matter, helping investors discover high-potential companies and evaluate emerging opportunities with confidence.

Contact
benh@investorstape.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements that may regard NeOnc Technologies Holdings’ future revenue, growth trajectory, profitability outlook, expansion plans, strategic partnerships, potential regulatory approvals, and other projections, plans, and objectives. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including market conditions, timing of venue openings, execution risks, operational performance, competition, regulatory matters, and general economic conditions. Readers should not place undue reliance on these statements, which speak only as of the date made.

General Disclaimer:

InvestorsTape.com has been compensated for press and editorial coverage of NeOnc Technologies Holdings and further disclosure information is available here. This communication is provided for informational and journalistic purposes only and reflects the independent editorial views of InvestorsTape.com.

This editorial discusses investigational therapy and clinical-trial results and is not medical advice or a recommendation to buy or sell securities.

This publication is protected speech under the First Amendment of the United States Constitution. Nothing herein constitutes an offer, solicitation, or recommendation to buy or sell any security, nor should it be construed as investment advice. Investing in securities involves risk, including the possible loss of principal. Readers are encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decision.

On 29 September 2026, Enefit OÜ, wholey owned subsidiary of Eesti Energia AS, officially opened the Kelmė I and Kelmė II wind farms in Lithuania. The projects add a combined 167 MW of renewable electricity generation capacity to Lithuania’s electricity system. Enefit invested approximately EUR 324 million in the development of the wind farms.

The two wind farms are expected to generate approximately 530 GWh of electricity annually, contributing to greater energy security and increasing domestic renewable electricity production in Lithuania.

In addition, Enefit is developing battery energy storage systems with capacities of 16 MW and 18 MW at the Kelmė sites. The company plans to invest more than EUR 30 million in energy storage solutions across its Lithuanian wind farm portfolio, supporting the integration of renewable energy and enhancing the stability and flexibility of the electricity system.

Following the commissioning of Kelmė I and Kelmė II, Enefit operates nine wind farms in Lithuania with a combined installed capacity exceeding 400 MW.

Danel Freiberg
Head of Treasury and Financial Risk Management

Eesti Energia AS
+372 5594 3838 | danel.freiberg@enefit.com
Lelle 22, 11318 Tallinn | www.enefit.com

  • 15% savings on Air Canada flight rewards for Aeroplan Credit Cardholders, available to Canadian cardholders as a promotional offer through January 11, 2027, becoming a card benefit on January 12, 2027
  • Cardholders will also receive semi-annual Air Canada Flight Benefit through their AC Wallet
  • Aeroplan Premium Credit Cardholders will gain access to Maple Leaf Lounges worldwide with one guest, as well as Priority Security lanes at select airports for themselves and up to eight companions travelling on the same reservation
  • Aeroplan Credit Cardholders will enjoy a 4th Day Free on eligible car rental redemptions, and a 4th Night Free for hotel redemptions – an ongoing card benefit starting January
  • All other existing card benefits remain unchanged

MONTRÉAL, Sept. 29, 2026 (GLOBE NEWSWIRE) — Aeroplan, Canada’s leading loyalty program today announced a major refresh of its Canadian co-branded credit card portfolio with new benefits starting January 12, 2027, designed to elevate the travel journey. The upgrades build on Aeroplan’s category-leading offering, delivering savings to cardholders as they plan, book and enjoy travel.

Aeroplan Credit Cards to Include New Travel Benefits and 15% Savings on Air Canada Flight Rewards

“A great credit card should be rewarding every time you use it and offer benefits that fit the way you travel,” said Scott O’Leary, Vice President, Loyalty and Product, Air Canada. “With new savings on flights, car and hotel redemptions, along with new features that bring comfort and convenience at the airport, these changes across our Aeroplan Credit Card portfolio are designed to deliver benefits to our members at every stage of the travel journey.”

More Ways to Save When You Travel

Aeroplan is introducing simple, easy-to-use new cardholder benefits across the travel journey:

  • 15% Off Flight Rewards: Starting January 12, 2027, all primary Aeroplan Credit Cardholders will save 15% in points when they redeem for Air Canada flight rewards, helping points go further on every trip.
  • Air Canada Flight Benefits via AC Wallet: Premium Cardholders will get up to $100 annually toward Air Canada travel, with $50 available twice a year. Core Cardholders will get up to $50 annually toward Air Canada travel, with $25 available twice a year. The first benefit will be available on January 15, 2027.
  • A 4th Day Free on Car Rental Redemptions: Building on Aeroplan’s popular 4th Night Free hotel benefit, Aeroplan Credit Cardholders will also get a 4th Day Free when redeeming Aeroplan points for eligible car rentals, as an ongoing card benefit.
  • A 4th Night Free on Hotel Redemptions: Previously a limited-time promotion, this benefit will become an ongoing card benefit as of January 12, 2027, allowing Aeroplan Credit Cardholders to redeem points for a 4th Night Free on eligible hotel stays.
  • Existing Travel Benefits Continue: Cardholders will continue to enjoy the benefits already included with their eligible cards. All other existing card benefits remain unchanged, including free first checked bags and priority boarding for eligible cards.

New Benefits for Aeroplan Premium Credit Cardholders
Aeroplan Premium Credit Cardholders will enjoy a smooth and comfortable airport experience with new premium benefits, subject to standard access terms:

  • Elevated Airport Benefits: A benefit that previously applied only in North America will now extend access for Premium Cardholders, plus one travel companion, to Air Canada Maple Leaf Lounges worldwide. This is in addition to Air Canada Café access currently available at locations across Canada.
  • Priority Security Clearance: Premium Cardholders will now have access to dedicated Priority Security lanes at select airports worldwide for themselves and up to eight companions travelling on the same reservation.
  • Existing Exclusive Premium Benefits Continue: Premium Cardholders will continue to enjoy many of the benefits they love today, including Priority Check-In, Priority Boarding, Priority Baggage Handling, Priority Airport Standby, 10% Head Start, up to 25,000 Status Qualifying Credits, and more.

Aeroplan Credit Card Benefits for Every Stage of Travel

The Aeroplan Credit Card benefits members know and use today will continue, alongside new benefits across the travel journey. Additional information will be available soon through cardholders’ financial institutions. Aeroplan Credit Cardholders can also continue to earn Aeroplan points on everyday purchases through Aeroplan’s extensive network of partners, including Starbucks, Uber, LCBO and more than 900 Avolta airport retail stores.

These portfolio-wide upgrades are part of Aeroplan’s ongoing commitment to delivering exceptional card benefits that support members throughout their travel journey.

For more details on the new Aeroplan Credit Card benefits, including eligibility requirements and applicable terms and conditions, please visit aircanada.com.

Aeroplan Celebrated at the 2026 Freddie Awards
This year marks Aeroplan’s fourth consecutive winning year at the Freddie Awards, the travel loyalty industry’s most respected honours, based on votes from more than 10 million loyalty members globally. Aeroplan is proud to be recognized for earning several top honours at this year’s Freddie Awards in the Americas region, including Program of the Year, Best Redemption Ability, and Best Promotion for its Accelerate Your Way to Status campaign.

About Aeroplan
Air Canada’s Aeroplan is Canada’s leading travel loyalty program, with more than 10 million active members worldwide. Aeroplan Members can earn or redeem points with over 50 airlines to 1,300+ destinations globally, without blackouts or surcharges. Redeem for one-way short-haul flights starting at 6,000 points, Air Canada Vacations packages, and 9,000+ hotel partner properties, or shop brands like Amazon, Apple, and Dyson via the Aeroplan eStore, with redemptions starting at 3,500 points. To join Aeroplan and start turning daily purchases into points for flights, hotel stays, gifts and more, visit aircanada.com/aeroplan.

About Air Canada
Air Canada is Canada’s largest airline, the country’s flag carrier and a founding member of Star Alliance, the world’s most comprehensive air transportation network. Headquartered in Montréal, Air Canada provides scheduled service directly to more than 180 airports in Canada, the United States and internationally on six continents. It holds a Four-Star ranking from Skytrax. Air Canada’s Aeroplan program is Canada’s premier travel loyalty program, with more than 10 million members worldwide. Members can earn or redeem points on the world’s largest airline partner network of more than 50 airlines, plus through an extensive range of merchandise, hotel and car rental partners. Through Air Canada Vacations, it offers a selection of vacation and Flight & Hotel packages, tours, cruises, car rentals, and experiences. Its freight division, Air Canada Cargo, provides air freight lift and connectivity to hundreds of destinations across six continents using Air Canada’s passenger and freighter aircraft. Air Canada’s climate-related ambition includes a long-term aspirational goal of net-zero greenhouse gas emissions by 2050. For additional information, please see Air Canada’s TCFD disclosure. Air Canada shares are publicly traded on the TSX (AC).

Contacts:        media@aircanada.ca

Internet:        aircanada.com/media

Read our annual report Here

Sign up for Air Canada news: aircanada.com

Media Resources:
Photos
Videos
B-Roll
Articles

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4afe2140-6493-4637-8eca-5e0aef207f2d

Vivos Management is Executing on Plan to Immediately Reduce Overhead by an Estimated $3.6 million Annually While Also Driving Top-Line Revenue

LITTLETON, Colo., Sept. 29, 2026 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea (“OSA”) and other breathing and sleep disorders, today announced execution by management on a restructuring and cost reduction plan aimed at saving an estimated $3.6 million annually, beginning in Q4 2026. Parts of the plan have already been implemented, with additional reductions going into effect October 1, 2026. The primary savings in the plan come from staff reductions, vendor relationship changes, negotiated contract savings, and more. The Company expects the full measure of cuts to take place in the fourth quarter of 2026.

In addition to the announced expense reductions, management has also pursued a number of revenue growth initiatives that are beginning to deliver meaningful financial returns. Consistent with the Company’s previously announced growth, referrals into the Company’s Las Vegas Sleep and Airway Medicine Centers continued to rise approximately 3-fold from the first of June through September 27. Revenue from the recent surge in referrals is expected to begin showing up in the fourth quarter and into 2027.

Additional revenue is expected from the Company’s EEG diagnostic testing and treatment initiative, which has also grown from near zero in May to a projected annualized run rate of between $1.5 and $3.0 million in the fourth quarter. The Company is also executing on a Remote Patient Monitoring (RPM) program that is expected to add to top line revenue at an annualized rate of up to $3.5 million by the first quarter of 2027.

Vivos management is also actively engaged in renegotiating legacy payer contracts to bring them up to market rates. The expected range of revenue impact is between $2.4 million and $5.6 million, with very little associated costs. The full realization of these fee increase are expected in early 2027 and throughout the next six to nine months.

R. Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer, stated, “Our management team is laser focused on all of our restructuring and revenue growth initiatives. Perhaps the most compelling is our ongoing conversions and replacement of legacy IT and software systems and infrastructure that dramatically leverage AI and allow us significant and material labor savings.”

When all of these operational expense reductions and revenue growth initiatives are factored in, Vivos management believes the Company will be on track to meet its stated objective of being cash flow positive by late 2026 or early 2027 and profitable in 2027.

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (Nasdaq: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the flagship DNA appliance is the first to receive clearance for treating moderate to severe OSA in children.

OSA affects an estimated one billion adults aged 30-69 years old worldwide, yet 80% or more remain undiagnosed and unaware of their condition. These chronic disorders are not just a sleep issue—they are closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, legacy OSA treatments like CPAP are often mechanistic and fail to address the root causes. Vivos CARE oral medical devices are designed to help address anatomical factors often associated with OSA.

Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly..

A 2019 analysis published in The Lancet Respiratory Medicine estimated that approximately 936 million adults aged 30 to 69 worldwide have OSA. Through technology, education, provider partnerships and acquisitions, Vivos seeks to expand access to more comprehensive and personalized OSA diagnosis and treatment.

Vivos calls the use of its appliances and related clinical protocols to treat OSA The Vivos Method, a proprietary, clinically effective solution that is a nonsurgical, noninvasive, and nonpharmaceutical approach designed to address the complex needs of OSA patients, and which provides hope to allow patients to Breathe New Life.

For more information, visit www.vivos.com.

Cautionary Note Regarding Forward-Looking Statements

This press release, including statements of the Company’s management and other parties made in connection therewith, contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning future events. Words such as “may,” “would,” “should,” “expects,” “projects,” “potential,” “intends,” “plans,” “believes,”, “hopes”, “anticipates,” “estimates,” “goal,” “aim,” and variations of such words and similar expressions are intended to identify forward-looking statements.

Forward-looking statements in this press release include, without limitation, statements regarding the anticipated future impact on the Company’s the estimated annual expense savings from the Company’s cost reduction initiatives, including the assumption that such savings will approximate $3.6 million on an annualized basis; the Company’s expectations regarding patient demand and medical referrals; and the Company’s goal of becoming cash flow positive.

These statements involve significant known and unknown risks and are based on assumptions and estimates subject to uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to effectively market or sell products or continue to integrate business from the acquisition and alliance model into its own or otherwise implement sales, marketing, and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos’ products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea diagnosis and treatment sector; (iv) the risk that Vivos may be unable to secure additional financing to continue operations, acquire additional sleep centers practices or enter into management services support affiliations on reasonable terms, or maintain its Nasdaq listing when needed, if at all, (v) the risk that actual cost savings from cost reduction initiatives may be less than estimated or may be offset by transition costs, severance obligations, or operational disruptions, (vi) the risk that restructuring and revenue growth initiatives and reimbursement rate changes may not be as significant as expected, (vii) the risk that patient volume increases may not materialize at the pace or magnitude anticipated, (viii) market and other conditions that could impact Vivos’ business or ability to obtain financing; and (ix) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (the “SEC”), which are available free of charge at www.sec.gov.

Except as required by applicable law, Vivos undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.

Vivos Investor Relations Contact:

Jennifer Hauser, Executive Assistant to the CEO
jhauser@vivoslife.com
720-927-3125

  • Rapid completion of Part A enrollment underscores strong operational execution and investigator engagement in relapsed or refractory acute myeloid leukemia
  • Full Part A population expected to provide important efficacy insights across subjects who relapsed from or were refractory to first line (1L) AML treatment, including intensive 7+3 and venetoclax-based regimens
  • Expect final Part A dataset to approximate 50/50 between 1L 7+3 and venetoclax-based regimens
  • Absence of cardiotoxicity continues to differentiate Annamycin from conventional anthracyclines

HOUSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML), with 89 subjects enrolled and an additional subject currently in screening. With Part A enrollment closed, the Company remains on track for its planned comprehensive data readout of Part A in the first quarter of 2027.

The rapid pace of enrollment underscores the significant unmet need in R/R AML as well as strong engagement from investigators and clinical sites participating in MIRACLE. The Company expects the expanded Part A dataset to provide important insight into the potential efficacy of AnnAraC across subjects who have relapsed from or are refractory to different first-line (1L) AML treatment approaches, including subjects previously treated with intensive 7+3 chemotherapy and those previously treated with venetoclax-based regimens. Such treatment approaches associated with 1L patient populations are commonly, while not universally, deemed as “fit” and “unfit”, respectively.

“Completing enrollment in Part A of MIRACLE is an important milestone for Moleculin and a strong demonstration of the operational execution behind this pivotal program,” said Walter Klemp, Chairman and Chief Executive Officer of Moleculin. “We have maintained a rapid pace of enrollment in a global, randomized AML trial and, importantly, remain on track in the first quarter of 2027 for our planned comprehensive data readout – one much deeper in data than our first interim n45 readout. Our focus turns to the maturation and analysis of this substantially larger dataset and what it may tell us about the potential of AnnAraC across distinct and clinically important R/R AML patient populations such as “fit” and “unfit” subjects.”

Mr. Klemp continued, “We are particularly excited about the composition of the additional subjects enrolled in Part A and the opportunity that the full Part A population may provide to better understand efficacy based on prior 1L treatment. We estimate that Part A will end with approximately a 50/50 split between “fit” and “unfit” subjects, compared to a roughly 70/30 split, respectively, in the first 45 subjects in Part A. While we are mindful that this shift in composition to more “unfit” subjects represents a more challenging environment for achieving treatment responses, it should provide valuable insight into Annamycin’s ability to fill critical unmet needs. Lastly, we continue to see a lack of cardiotoxicity in MIRACLE’s blinded data.”

“Completing Part A enrollment reflects the execution of our team and investigators and moves us directly toward what we believe will be one of the most important milestones in Annamycin’s development,” Mr. Klemp added. “We are grateful to the patients and families participating in MIRACLE and to the investigators and clinical teams whose commitment has enabled us to reach this milestone at such a rapid pace. With enrollment complete and the trial on track for a comprehensive Q1 2027 readout, we believe Moleculin is entering a potentially defining period for the MIRACLE program.”

About the MIRACLE Trial

MIRACLE is a pivotal Phase 2/3 study of Annamycin in combination with cytarabine for the treatment of adult subjects with AML who are refractory to, or have relapsed (R/R) after, induction therapy. Part A of the trial is a randomized, double-blind portion of the study that compares two different doses of Annamycin plus cytarabine to a control arm of cytarabine plus placebo, all with just one cycle of therapy.

Importantly, as specified by the MIRACLE protocol, remission rates for all three arms, including the control arm, reflect outcomes measured after only a single cycle of therapy. The most commonly cited historical benchmarks in this setting, including the MIRROS and CLASSIC I studies, as well as Moleculin’s own MB-106 study, permitted multiple cycles of treatment. The Company therefore expects absolute remission rates for both the control and Annamycin arms to be lower than those reported in such multi-cycle datasets and believes the most meaningful comparison is the performance of the Annamycin arms relative to the concurrent, randomized control arm evaluated on the same single-cycle basis.

The comprehensive Part A analysis is expected to evaluate efficacy and safety across the complete randomized population and support selection of the optimal Annamycin dose for advancement into Part B of MIRACLE.

For additional information on the MIRACLE trial, please visit ClinicalTrials.gov and reference Identifier NCT06788756.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), has shown to be an efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company is conducting the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine (also referred to as “Ara-C”), together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway toward a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML, expected timing of the comprehensive Part A data readout in Q1 2027, the anticipated composition of the Part A population including the expected approximate 50/50 split between fit and unfit subjects, the potential for Part A data to support dose selection for Part B, and the expectation that interim efficacy trends observed in a limited patient population will be confirmed in the full study population. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

Two-year agreements support vehicle registration enforcement and establish a citation-based processing fee model in a new state

SALT LAKE CITY, Sept. 29, 2026 (GLOBE NEWSWIRE) — OMNIQ CORP. (OTCQB: OMQS) (“OMNIQ” or the “Company”), a provider of AI-based computer vision solutions, today announced that two Pennsylvania municipalities have selected Q Shield™, its Safe City platform, for vehicle registration enforcement. The agreements mark OMNIQ’s first deployments in Pennsylvania. One is with a borough in the northeast; the other is with a township in the southeast.

Q Shield™ identifies vehicles with suspended, revoked or expired registrations and, at one of the two sites, vehicles without required insurance coverage. It sends potential violations to authorized officers, who review the information and make the final enforcement decision. Officers can review activity remotely, extending coverage along busy roads without remaining stationed at a camera. The platform can also support other public safety alerts and investigations according to an agency’s configuration and authority.

The initial deployments will include a combined 18 cameras across nine intersections along corridors carrying approximately 80,000 vehicles per day, based on PennDOT traffic data. Both projects are expected to go live in 2026. OMNIQ is also in discussions with additional Pennsylvania municipalities.

Under the two-year agreements, OMNIQ will receive a processing fee associated with citations issued following agency review and authorization. The fee model creates a transaction-based recurring revenue opportunity tied to enforcement activity. Both agreements include a six-month evaluation period. Each department retains control over enforcement decisions according to its policies, staffing and applicable law.

“These agreements demonstrate the value and scalability of Q Shield for municipalities seeking to expand public-safety capabilities without proportionally increasing personnel,” said Shai Lustgarten, CEO of OMNIQ. “Pennsylvania represents a new market for the platform and a repeatable transaction-based revenue opportunity for OMNIQ. With two municipalities moving toward deployment and additional communities in discussion, we believe Q Shield can become an important part of our recurring-revenue growth strategy.”

ABOUT OMNIQ

OMNIQ CORP. uses patented and proprietary artificial intelligence to deliver machine vision image processing solutions, including data collection, real-time surveillance and monitoring for supply chain management, homeland security, public safety, traffic and parking management, and access control applications.

Our solutions help clients move people, assets and data safely and securely through airports, warehouses, schools, national borders and other environments.

Our principal solutions include hardware, software, communications, automated management services, technical services and support. Our experienced team helps customers simplify integration and deploy practical solutions across complex operating environments.

Privacy and Data Security Commitment

OMNIQ solutions are built to meet the privacy and data protection requirements of the agencies that use them. License plate data is processed and stored in a private network, and access is limited to authorized personnel at the contracting agency. Data is retained and purged according to the agency’s policy and applicable state law. OMNIQ does not sell plate data or share it with third parties for commercial purposes.

For more information about OMNIQ Corp. and its innovative solutions, please visit www.omniq.com.

INFORMATION ABOUT FORWARD LOOKING STATEMENTS

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

This release contains “forward-looking statements” that include information relating to future events and future financial and operating performance. The words “anticipate,” “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Examples of forward-looking statements include, among others, statements made in this press release regarding the expected timing of the Pennsylvania deployments, anticipated citation processing fee revenue, and additional municipal agreements. Important factors that could cause these differences include, but are not limited to: fluctuations in demand for the Company’s products, the introduction of new products, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, the Company’s ability to manage credit and debt structures from vendors, debt holders and secured lenders, the Company’s ability to successfully integrate its acquisitions, and other information that may be detailed from time-to-time in OMNIQ Corp.’s filings with the United States Securities and Exchange Commission. Examples of such forward-looking statements in this release include, among others, statements regarding revenue growth, driving sales, operational and financial initiatives, cost reduction and profitability, and simplification of operations. For a more detailed description of the risk factors and uncertainties affecting OMNIQ Corp., please refer to the Company’s recent Securities and Exchange Commission filings, which are available at SEC.gov. OMNIQ Corp. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless otherwise required by law.

Contact

IR@OMNIQ.COM

Company

HAYDEN IR:
Brett Maas
(646) 536-7331
brett@haydenir.com

James Carbonara
(646)-755-7412
james@haydenir.com

DLR Kredit A/S
Andre oplysningsforpligtelser offentliggjort efter børsens regler

DLR Kredit har fastsat kuponrenter for perioden 1. oktober 2026 til 4. januar 2027
på følgende Senior Non-Preferred Notes (SEK og NOK):

ISIN Navn Referencerente NyRente
DK0030576079 SNP SEK July 2030 STIBOR3M 3,183%
NO0013754481 SNP NOK July 2030 NIBOR3M  5,890% 

Spørgsmål kan rettes til Fonds og Funding, fonds@dlr.dk eller pr. tlf 33 42 07 38

Med venlig hilsen
DLR Kredit

Attachment

Dr. Chung to deliver an oral presentation highlighting QUELIMMUNE®, an advanced extracorporeal therapy for critically ill pediatric patients with acute kidney injury (AKI)

DENVER, Sept. 29, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that its Chief Medical Officer, Kevin Chung, M.D., will deliver an invited talk at the 2026 PPETS conference, hosted by Texas Children’s Hospital in Houston, Texas, October 6 – 8, 2026.

The annual PPETS conference gathers leading international pediatric nephrologists, intensivists, neonatologists, and extracorporeal therapy specialists to share innovations in pediatric continuous renal replacement therapy (CRRT), extracorporeal membrane oxygenation (ECMO), and related therapies. It addresses practice variation, emerging technologies, and evidence gaps through expert-led sessions, case discussions, and simulation-based training.

“I’m grateful to the PPETS organizers for the opportunity to participate in this important meeting,” said Dr. Chung. “I look forward to sharing lessons from our experience with QUELIMMUNE and discussing what we’ve learned about translating medical innovation into delivering improved outcomes to the most vulnerable patients.”

Dr. Chung’s presentation will highlight lessons learned in medical device innovation, using QUELIMMUNE as an example of the journey, from identifying an unmet clinical need to bringing a new therapy to the bedside. He is one of four presenters at the following session that also includes a session by James Odum, M.D., Pediatric Critical Care Medicine, Children’s Hospital of Alabama, regarding the use of SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy:

The Future of Pediatric Extracorporeal Therapies Innovation, Emerging Technologies, and the Next Generation of Support

Date & Time: Tuesday, October 6, 2026, 8:30 am to 10:00 am CDT

Presentations Include:

Dynamic renal monitoring: Are Daily Serum Creatinine a Thing of The Past?

Stuart Goldstein, M.D., Director, Center for Acute Care Nephrology, Cincinnati Children’s Hospital Medical Center

Endotoxin Removal: Reversing Triggers of Immune Dysregulation

John Kellum, M.D., Distinguished Professor of Critical Care Medicine, University of Pittsburgh School of Medicine

Taming Monocytes and Neutrophils: Reversing Severe AKI by Leveraging Selective Cytopheretic Devices

James Odum, M.D., Pediatric Critical Care Medicine, Children’s Hospital of Alabama at University of Alabama

Pipeline for Device Development: How to Support The Next Generation of Thinkers

Kevin Chung, M.D., Chief Medical Officer, SeaStar Medical

About QUELIMMUNE

The QUELIMMUNE® (SCD-PED) therapy is being commercialized for children with AKI and sepsis or septic condition weighing 10 kilograms or more who are on antibiotics and being treated in the ICU with RRT. It was approved in February 2024 under a Humanitarian Device Exemption application.

Data from two clinical trials of the QUELIMMUNE therapy, published in Kidney Medicine, showed a 77% survival rate in patient treated with QUELIMMUNE versus standard of care, representing an approximate 50% reduction in loss of life compared to historical data in this patient population. No dialysis was required for survivors, and 87.5% of survivors had normal kidney function at Day 60 after ICU discharge. In February 2026, data published in the prestigious, peer-reviewed journal, Pediatric Nephrology, highlighted the early experience from the QUELIMMUNE SAVE Registry, a post-approval surveillance registry, evaluating the role of the QUELIMMUNE therapy in the treatment of critically ill pediatric patients with life-threatening Acute Kidney Injury (AKI) and sepsis requiring renal replacement therapy. Observations from the first 21 pediatric patients with AKI and sepsis requiring renal replacement therapy showed no device-related adverse events or infections and no reports of immunosuppressive effects by the device. In addition, preliminary outcomes analyses show a 76% survival rate at Day 28 and Day 60, and a 71% survival rate at Day 90. These new data are on track to validate a 50% reduction in patient mortality at 60 days compared to historical data, similar to what was observed in the registration study reported in Kidney Medicine.

The patented technology behind QUELIMMUNE is known as the Selective Cytopheretic Device (SCD) therapy and has broad applications for treating the destructive hyperinflammation that shuts down organ function and causes loss of life.

About the SeaStar Medical Selective Cytopheretic Device (SCD) Therapy

The SCD therapy is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The SCD therapy is designed for broad applications in multiple acute and chronic kidney and cardiovascular diseases, representing patients who today have no FDA-approved options for treating their disease. Unlike pathogen removal and other blood-purification tools, the SCD therapy is integrated with an existing continuous RRT hemofiltration system to selectively target and transition proinflammatory monocytes to a reparative state and promote activated neutrophils to be less inflammatory. This unique immunomodulation approach may promote long-term organ recovery, eliminate the need for future continuous RRT, including dialysis, and prevent loss of life.  

About NEUTRALIZE-AKI Pivotal Trial

The NEUTRALIZE-AKI (NEUTRophil and monocyte deActivation via SeLective Cytopheretic Device – a randomIZEd clinical trial in Acute Kidney Injury) pivotal trial is evaluating the safety and efficacy of the SCD therapy in 339 adults with AKI in the ICU receiving continuous RRT. The trial’s primary endpoint is a composite of 90-day mortality or dialysis dependency of patients treated with the SCD therapy in addition to continuous RRT as the standard of care, compared with the control group receiving only continuous RRT standard of care. Secondary endpoints include mortality at 28 days, ICU-free days in the first 28 days, major adverse kidney events at Day 90 and dialysis dependency at one year. The study will also include subgroup analyses to explore the effectiveness of the SCD therapy in AKI patients with sepsis and acute respiratory distress syndrome. 

About Acute Kidney Injury (AKI) and Hyperinflammation 

AKI is characterized by a sudden and temporary loss of kidney function and can be caused by a variety of conditions such as severe infections or other septic conditions, severe trauma, surgery, and organ failures. AKI can cause destructive hyperinflammation, which is the overproduction or overactivity of inflammatory effector cells and other molecules that can be toxic. Damage resulting from this destructive hyperinflammation in AKI can progress to other organs, such as the heart or liver, and potentially to multi-organ dysfunction or even failure that could result in worse outcomes, including increased risk of death. Even after resolution, these patients may face complications including chronic kidney disease or end-stage renal disease (ESRD) requiring dialysis. Extreme hyperinflammation may also contribute to added healthcare costs, such as prolonged ICU stays and increased reliance on dialysis and mechanical ventilation.

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch.

For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect to commercial acceptance of QUELIMMUNE; the ability of SCD to treat patients with AKI and other diseases; the expected regulatory approval process and timeline for commercialization; and the ability of SeaStar Medical to meet the expected timeline. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to secure additional financing on acceptable terms; (vi) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. 

Contact:  
IR@SEASTARMED.COM

QUELIMMUNE is a registered trademark of SeaStar Medical Holding Corporation.

Following termination of ATM, Company has substantially utilized its shelf capacity

Company also strengthens Board with the addition of two seasoned mining directors

CHARLOTTE, N.C., Sept. 29, 2026 (GLOBE NEWSWIRE) — via IBN – Greenland Mines Ltd (“Greenland Mines” or the “Company”) (Nasdaq: GRML; FSE: HK6), a Greenland-focused mineral resource development company, today announced that it has raised over $17 million through a registered direct offering of common stock at a purchase price of $13.00 per share, bringing total capital raised by the Company over the past week to over $59 million. The financing materially strengthens the Company’s balance sheet and provides the capital required to execute its planned exploration and development programs and achieve its 2027 milestones across its Greenland portfolio. The financing substantially utilized the remaining capacity under the Company’s existing shelf registration statement.

The Company also announced the addition of Blair Jordan and Peter Love to its Board of Directors.

Mr. Jordan is an experienced public-company executive, director, investment banker and attorney who currently serves as Chief Executive Officer and a director of Tungsten Reserve Corp. and as an independent director and Chair of the Audit Committee of Standard Uranium Ltd. He previously served as Chief Executive Officer and a director of Forum Markets, Incorporated, where he led a restructuring and subsequently completed a $425 million private placement. Earlier in his career, he served as a Managing Director and Corporate Director of Ventum Financial and spent nearly a decade with Credit Suisse in principal investing, leveraged finance, restructuring, special situations and convertible bonds. He began his career as a securities lawyer with Bennett Jones LLP.

Mr. Love has more than 18 years of experience in mineral exploration and corporate finance for the natural-resources industry. He is Executive Chairman and co-founder of Torino Metals and previously co-founded Proximo Resources, which was acquired by Rugby Mining Limited, following which he served as a director and Chief Executive Officer of Rugby Mining. He also previously served as Chairman of Intrepid Mines Limited and Chairman of Talon Petroleum Limited.

About Greenland Mines Ltd

Greenland Mines Ltd is a Nasdaq-listed resource development and mining company focused on the development of the Skaergaard Project in southeast Greenland and the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and select midstream processing opportunities, while advancing its assets and broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are often identified by words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “potential,” “could,” “may,” “will,” “should,” “estimate,” “objective” and similar expressions.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties. Many factors could cause actual results to differ materially, including exploration, resource-estimation, metallurgical, engineering, environmental, social, permitting, logistical, infrastructure, financing, commodity-price, market, counterparty and execution risks; changes to planned programs and timelines; the Company’s ability to obtain required approvals and financing; and risks described in documents filed or to be filed with the U.S. Securities and Exchange Commission. No assurance can be given that studies, applications, partnerships, transactions, development decisions or production will occur on the timing contemplated or at all.

Readers should carefully consider these factors and the other risks and uncertainties described in the Company’s SEC filings. All information in this press release is provided as of its date, and the Company undertakes no obligation to update any forward-looking statement except as required by applicable law.

Investor Contact and Corporate Communications:

ir@greenlandmines.com
Website: www.greenlandmines.com

Corporate Communications:

IBN
Austin, Texas
IBN.Ai
512.354.7000 Office

Editor@IBN.Ai

DENVER, Sept. 29, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) — Kraig Biocraft Laboratories (OTCQB: KBLB) reached a significant commercialization milestone, announcing the shipment of its first commercial order of recombinant spider silk yarn to a globally recognized performance sports brand. The custom-engineered yarn was produced to the customer’s specifications and is intended for development into a first-of-its-kind performance textile. While the shipment is small by design and part of a confidential pilot program, the significance is that Kraig’s material has moved beyond laboratory and scaled-production demonstrations into an actual customer development program targeting one of the most demanding segments of the textile market.

Kim Thompson, CEO and founder of Kraig Labs, described the delivery as “a huge milestone for Kraig Labs,” emphasizing that the project is designed around a precision application where spider silk’s combination of strength, flexibility, toughness and low weight can potentially provide differentiated performance. Thompson added, “High-performance sport is where materials prove themselves,” framing the customer program as an opportunity to demonstrate whether recombinant spider silk can translate its laboratory characteristics into a commercially relevant textile application.

Kraig Labs First Commercial Spider Silk for High-performance Athletic Apparel Pilot Development Program

The timing is notable against a massive global fiber market. Textile Exchange reported that worldwide fiber production reached a record 139 million metric tons in 2025, with polyester representing 59% of global production and 88% of polyester output coming from virgin fossil-based sources. Against that backdrop, new performance fibers face a dual challenge: demonstrating meaningful technical advantages while proving they can be produced consistently enough for commercial applications. Kraig has been pushing toward that scale, reporting more than 1.3 metric tons of spider silk cocoons produced in a single month earlier this year.

However, performance apparel is only one potential market for a material engineered around the unusual combination of strength, toughness, flexibility and low weight associated with spider silk. High-performance protective equipment, aerospace and aviation components, automotive materials, advanced composites, technical textiles, ropes and cables, filtration, medical devices and wound-care materials are among the broader categories that have attracted research interest in spider-silk-based materials. In medical applications, researchers have investigated spider silk proteins and fibers for areas including tissue engineering, drug delivery and wound-healing materials, while advanced-material researchers have explored their potential as components in lightweight composites and other high-performance structures.

Kraig Labs Packs Recombinant Spider Silk Yarn for Its First Commercial Delivery

Defense and protective applications represent another potentially important target because materials that combine low weight with strength and toughness can be valuable in applications where reducing weight without sacrificing performance is critical. Potential uses can include protective textiles, ballistic-related materials, technical fabrics and specialized load-bearing components. Automotive and aerospace applications similarly place a premium on lightweight materials that can withstand demanding mechanical environments. These are development opportunities rather than established commercial markets for Kraig, but they illustrate why the company’s strategy extends beyond conventional apparel.

Kraig’s commercial shipment also comes as its broader technology platform continues to advance. The company recently announced completion of its functional and living Atlas Gene Library, part of Project Atlas, which is designed to create new combinations of genetic elements and ultimately produce recombinant spider silk with customized performance characteristics. The company says the program is intended to expand strength, toughness and other properties, potentially allowing future fibers to be engineered around specific industrial, defense or commercial requirements. That ability to tune a fiber for a particular application could be especially important in advanced materials, where one customer may prioritize tensile strength while another could require elasticity, impact resistance, durability, lightweight construction or a combination of properties.

From a market perspective, the most compelling element is not simply that Kraig has shipped yarn, but that the company is beginning to test its material in a real-world product-development setting. Kraig previously reported testing showing that its commercially produced recombinant spider silk retained the strength and toughness demonstrated in earlier small-batch testing. National Geographic also recently spotlighted the company’s technology, including demonstrations in which Kraig’s silk was used to suspend a 170-pound tractor tire from a 0.35-ounce loop.

Thompson emphasized the significance of this order: “This is the kind of project that changes the conversation. When a brand at this level puts our material to the test, the results speak for themselves. We intend for this to be the first of many.”

The company is now attempting to bridge three increasingly important stages: production scale, customer validation and product integration. The first performance-brand shipment does not establish broad commercial adoption, recurring revenue or success in any of the other potential industries. Those applications would require additional development, customer validation and, in some cases, substantial regulatory and technical qualification.

The range of potential markets highlights the larger strategic opportunity: Kraig’s spider silk could potentially move from a novel textile material into a broader advanced-materials platform.

For Kraig Labs, Project Atlas adds another dimension to that opportunity. Rather than simply producing one standardized fiber, the company is pursuing the ability to develop increasingly specialized spider-silk materials tailored to specific performance requirements. If that approach succeeds, future generations could potentially be designed around greater strength, elasticity, toughness, lightweight construction or other characteristics demanded by particular customers and industries.

The first commercial shipment therefore represents more than a box of yarn leaving a production facility. It is an early confirmation that recombinant spider silk is transitioning from scientific achievement to customer-qualified material and potentially the first step toward much broader markets for engineered spider-silk technologies.

About 24/7 Market News

In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/b530c2f4-3cc7-4beb-8af3-29eaf161525f

https://www.globenewswire.com/NewsRoom/AttachmentNg/ab979558-cd75-44fe-871b-5252d8888f89

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.